The new white label instruments are said to be fully-supported and ready-to-use systems that will help OEM’s to accelerate product development, in addition to increasing product quality, precision and accuracy while decreasing cost.
BIT Group CEO Marius Balger said: "OEM’s must adhere to a growing number of evolving IVD regulatory requirements, while remaining innovative and competitive. Additionally, there is constant pressure to keep costs down and excel in the operation of their own businesses."
The firm’s resources are involved in developing a full range of white label and ready-to use IVD solutions that can be used in applications, including hematology, clinical chemistry and homeostasis diagnostics.
According to the firm, the white label IVD instruments are customizable with regard to functionality, consumables and reagents.
BIT offers contract product development, manufacturing and after-sales services for life science, medical and IVD instrumentation OEMs. The firm carries out operations in the US, Germany, France, China and Japan.
